uniQure N.V. Files 8-K Report
Ticker: QURE · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1590560
| Field | Detail |
|---|---|
| Company | Uniqure N.V. (QURE) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory
TL;DR
uniQure filed an 8-K, likely standard disclosures. No major news yet.
AI Summary
On September 23, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, with no specific material events or financial figures detailed in the provided text.
Why It Matters
This 8-K filing indicates uniQure N.V. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's regulatory compliance and financial status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate adverse events or significant financial changes.
Key Players & Entities
- uniQure N.V. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
- 001-36294 (company) — Commission File Number
- Paasheuvelweg 25a (location) — Address of Principal Executive Offices
- Amsterdam (location) — City of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing by uniQure N.V.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on September 23, 2024.
What is uniQure N.V.'s Commission File Number?
uniQure N.V.'s Commission File Number is 001-36294.
Where are uniQure N.V.'s principal executive offices located?
The principal executive offices are located at Paasheuvelweg 25a, 1105 BP Amsterdam, The Netherlands.
What is the standard industrial classification for uniQure N.V.?
The standard industrial classification for uniQure N.V. is Pharmaceutical Preparations [2834].
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-09-23 07:35:21
Filing Documents
- qure-20240923x8k.htm (8-K) — 34KB
- qure-20240923xex99d1.htm (EX-99.1) — 17KB
- qure-20240923xex99d1001.jpg (GRAPHIC) — 6KB
- 0001558370-24-012941.txt ( ) — 178KB
- qure-20240923.xsd (EX-101.SCH) — 3KB
- qure-20240923_lab.xml (EX-101.LAB) — 15KB
- qure-20240923_pre.xml (EX-101.PRE) — 10KB
- qure-20240923x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 23, 2024, uniQure N.V. (the " Company ") issued a press release announcing that the U.S. Food and Drug Administration has granted orphan drug designation to AMT-191, the Company's investigational gene therapy for the treatment of Fabry disease. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended (the " Securities Act "), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of uniQure N.V. dated September 23, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. UNIQURE N.V. Date: September 23, 2024 By: /s/ Jeannette Potts JEANNETTE POTTS Chief Legal and Compliance Officer